Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 71–80 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 71
- Medicine slug
- alvimopan
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
30±10 L
- Numeric value
- 30
- Unit
- L
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a0645b4-daf8-421f-b987-a4e478843c5d (opens source in a new tab)
Alvimopan label
Version not recorded · Effective date not recorded
Distribution The steady-state volume of distribution of alvimopan was estimated to be 30±10 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10e39d3b-8621-16f8-e063-6294a90a254e (opens source in a new tab)
Alvimopan label
Version not recorded · Effective date not recorded
Distribution: The steady-state volume of distribution of alvimopan was estimated to be 30±10 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cd584de-b704-4d26-8451-e3247ffb8d08 (opens source in a new tab)
Alvimopan label
Version not recorded · Effective date not recorded
Distribution: The steady-state volume of distribution of alvimopan was estimated to be 30±10 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59ef406b-79db-4efd-b993-08b937ac682b (opens source in a new tab)
Alvimopan label
Version not recorded · Effective date not recorded
Distribution: The steady-state volume of distribution of alvimopan was estimated to be 30±10 L.
Projected row 72
- Medicine slug
- amantadine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 57
- Source count
- 57
- Agreement rate
- 0.947368
- Recorded readings
17 ± 4 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 54
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 54 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da1837b5-fda2-48e0-91ba-d6eb2b991b55 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:743d1b73-f47e-4bbf-bb52-45b1e7f17308 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0e9b795-c0a1-4c95-928c-dacaaf9b3bb5 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfd129ae-8b0a-f118-b7d0-45d106290b63 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a10bf8b5-bf70-4090-b4b2-a0be252b9fe4 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c448cb3-7996-4a83-a9ad-23a00a431fbe (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ff05131-f634-4688-86e9-9bc33a8d11c4 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6311b46b-23cc-40c1-93c2-f7c92606386f (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52aa093c-82cc-4d81-b072-86a2b8adc9c5 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4157d9a7-a53f-4dde-b051-fe3e9a674913 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6ca4d20-72c5-496c-9ac7-1f5cb407a742 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3eb34af-6e25-4a3d-a7d2-e9a789e335cc (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5232b933-1df9-43b4-8ac2-61bfa4855e68 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2f7da34-ad78-4db3-9af1-bdd341e09f16 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5989098d-2855-4b5f-9a06-64a83656c078 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aa6bc18-1cee-4b6d-b7c3-0bac6a924ece (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20dad861-6ad1-4660-b315-8af57b294175 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:579e6c23-6286-4b80-88de-c86c0e5cc2b2 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38fccce5-1f1e-9350-e063-6394a90a045a (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f70c79a-92a4-4a38-bbdd-900adc4c2e93 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fcf5182-a666-4f38-879f-47f19de30dd5 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b54064bc-b3e1-4d83-be40-fcaddd2e99d0 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a016ab57-d18f-4a3b-b2ab-f91fecc1eef7 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d94073b-c064-c280-e063-6294a90af145 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c5e0c61-372b-4d1b-8882-e13f6af8fed0 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da693bb0-0cc8-485d-89a7-c8cf28d440f3 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5119801d-a5cb-4adf-96b2-08cc3a0ba594 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e578f11-6112-4a1f-8de4-a76870bb62c7 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f28c55c8-2754-a44d-e053-2a95a90ae798 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:609dc911-1e9d-4ebd-b64b-f44054e5582e (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25dd8a3c-6b11-2ea1-e063-6294a90a50cf (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:547904f3-84a3-1ccb-e063-6294a90a6fb6 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63d9d4aa-5f92-45b0-98d0-d6ec38b727cb (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be411327-5ac7-46df-b5e4-32a11b419b15 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb6e83d-e635-b150-e063-6294a90ad61d (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a8f16cc-e5d5-4097-8297-10c8166c7a0e (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3810649-1301-4332-85df-722b36867b1b (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56b923c3-1d4a-47bf-9c9e-c0fdc54c8a2f (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a99bb98-82a4-4b9e-9216-554dade72a3c (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f3c7c37-c488-4a88-8251-7db52dc03827 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b9e7f0-be6d-4f37-9277-54bb0ba8b158 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd54e00-a714-4442-af95-2515ab3b2ac3 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96aefbca-fe71-42ef-8079-d0d9e7370ccb (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9498b7-125e-4314-baca-b62af6e5511c (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1211ebf4-3169-20ca-e063-6294a90aee4d (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fa07c8-8b95-40d7-a0f5-132577dfb2c8 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd7f2a6-5a91-81a2-e063-6294a90a33db (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25af52ee-9b29-4c07-a383-62d4537b63e0 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4d8f36f-d668-4728-8dca-b1c22bd9aedb (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:487125c0-51e7-aea3-e063-6394a90a6930 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8887814-3e56-447e-8bc3-add1861e0cf7 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303c5b9d-5761-9fcd-e063-6394a90a8a2b (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:461e6444-189e-62ed-6c61-1c36a04459c6 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6326d7f5-4c7c-4541-8db1-c582f1525f60 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
16 hours
- Numeric value
- 16
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ff865f-78f3-4c94-b6a9-727a54944b28 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The mean plasma amantadine half-life at steady-state was approximately 16 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bee0631-0028-1314-e063-6394a90aaaed (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The mean plasma amantadine half-life at steady-state was approximately 16 hours.
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48c949e3-86e0-c639-e063-6294a90acdba (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The half-life was 17 ± 4 hours (range: 10 to 25 hours).
Projected row 73
- Medicine slug
- amantadine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 57
- Source count
- 55
- Agreement rate
- 0.981818
- Recorded readings
3.3 ± 1.5 hours
- Numeric value
- 3.3
- Unit
- hours
- Source records
- 54
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 54 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da1837b5-fda2-48e0-91ba-d6eb2b991b55 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:743d1b73-f47e-4bbf-bb52-45b1e7f17308 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0e9b795-c0a1-4c95-928c-dacaaf9b3bb5 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfd129ae-8b0a-f118-b7d0-45d106290b63 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a10bf8b5-bf70-4090-b4b2-a0be252b9fe4 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c448cb3-7996-4a83-a9ad-23a00a431fbe (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ff05131-f634-4688-86e9-9bc33a8d11c4 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6311b46b-23cc-40c1-93c2-f7c92606386f (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52aa093c-82cc-4d81-b072-86a2b8adc9c5 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4157d9a7-a53f-4dde-b051-fe3e9a674913 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6ca4d20-72c5-496c-9ac7-1f5cb407a742 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3eb34af-6e25-4a3d-a7d2-e9a789e335cc (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5232b933-1df9-43b4-8ac2-61bfa4855e68 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2f7da34-ad78-4db3-9af1-bdd341e09f16 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5989098d-2855-4b5f-9a06-64a83656c078 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aa6bc18-1cee-4b6d-b7c3-0bac6a924ece (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20dad861-6ad1-4660-b315-8af57b294175 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:579e6c23-6286-4b80-88de-c86c0e5cc2b2 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38fccce5-1f1e-9350-e063-6394a90a045a (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f70c79a-92a4-4a38-bbdd-900adc4c2e93 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fcf5182-a666-4f38-879f-47f19de30dd5 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b54064bc-b3e1-4d83-be40-fcaddd2e99d0 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a016ab57-d18f-4a3b-b2ab-f91fecc1eef7 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d94073b-c064-c280-e063-6294a90af145 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c5e0c61-372b-4d1b-8882-e13f6af8fed0 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da693bb0-0cc8-485d-89a7-c8cf28d440f3 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5119801d-a5cb-4adf-96b2-08cc3a0ba594 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e578f11-6112-4a1f-8de4-a76870bb62c7 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f28c55c8-2754-a44d-e053-2a95a90ae798 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:609dc911-1e9d-4ebd-b64b-f44054e5582e (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25dd8a3c-6b11-2ea1-e063-6294a90a50cf (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:547904f3-84a3-1ccb-e063-6294a90a6fb6 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63d9d4aa-5f92-45b0-98d0-d6ec38b727cb (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be411327-5ac7-46df-b5e4-32a11b419b15 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb6e83d-e635-b150-e063-6294a90ad61d (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a8f16cc-e5d5-4097-8297-10c8166c7a0e (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3810649-1301-4332-85df-722b36867b1b (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56b923c3-1d4a-47bf-9c9e-c0fdc54c8a2f (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a99bb98-82a4-4b9e-9216-554dade72a3c (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f3c7c37-c488-4a88-8251-7db52dc03827 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b9e7f0-be6d-4f37-9277-54bb0ba8b158 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd54e00-a714-4442-af95-2515ab3b2ac3 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96aefbca-fe71-42ef-8079-d0d9e7370ccb (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9498b7-125e-4314-baca-b62af6e5511c (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1211ebf4-3169-20ca-e063-6294a90aee4d (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fa07c8-8b95-40d7-a0f5-132577dfb2c8 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd7f2a6-5a91-81a2-e063-6294a90a33db (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25af52ee-9b29-4c07-a383-62d4537b63e0 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4d8f36f-d668-4728-8dca-b1c22bd9aedb (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:487125c0-51e7-aea3-e063-6394a90a6930 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8887814-3e56-447e-8bc3-add1861e0cf7 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303c5b9d-5761-9fcd-e063-6394a90a8a2b (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:461e6444-189e-62ed-6c61-1c36a04459c6 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range: 1.5 to 8.0 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6326d7f5-4c7c-4541-8db1-c582f1525f60 (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
The time to peak concentration was 3.3 ± 1.5 hours (range 1.5 to 8.0 hours).
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48c949e3-86e0-c639-e063-6294a90acdba (opens source in a new tab)
Amantadine label
Version not recorded · Effective date not recorded
Across studies, the time to Cmax (Tmax) averaged about 2 to 4 hours.
Projected row 74
- Medicine slug
- ambrisentan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
9 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20ab2fe-bc9f-48a3-b15a-e4bc9532c2ac (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32549c43-f8ff-422c-b42d-ca0877e661cf (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:725d4e73-6c83-477a-adc6-0ae4a133a844 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e418384-cae1-47ae-ac5e-afc845d694f6 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4396bab5-2851-62ef-e063-6294a90af76e (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37af3191-0ed3-4783-8747-065f1462f2d2 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4978a54-1799-43d6-85dd-05fa9de0a5d7 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:291a782a-77e1-8a8e-e1c8-2626f305c2b7 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8080b009-361b-4505-b09a-0d91a0e4a2c0 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fc6032f-94dc-4067-8b24-01990ec99db0 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dcdea4-d3da-4dc1-9193-6ebdb5b4e690 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82e51c75-fb78-4ad3-8bce-5e0581d60014 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fda3e8b5-267b-4690-85c2-78626986245c (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Although ambrisentan has a 15-hour terminal half-life, the mean trough concentration of ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of ambrisentan is about 9 hours.
Projected row 75
- Medicine slug
- ambrisentan
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20ab2fe-bc9f-48a3-b15a-e4bc9532c2ac (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32549c43-f8ff-422c-b42d-ca0877e661cf (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:725d4e73-6c83-477a-adc6-0ae4a133a844 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e418384-cae1-47ae-ac5e-afc845d694f6 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4396bab5-2851-62ef-e063-6294a90af76e (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37af3191-0ed3-4783-8747-065f1462f2d2 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4978a54-1799-43d6-85dd-05fa9de0a5d7 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:291a782a-77e1-8a8e-e1c8-2626f305c2b7 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8080b009-361b-4505-b09a-0d91a0e4a2c0 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fc6032f-94dc-4067-8b24-01990ec99db0 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dcdea4-d3da-4dc1-9193-6ebdb5b4e690 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82e51c75-fb78-4ad3-8bce-5e0581d60014 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fda3e8b5-267b-4690-85c2-78626986245c (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is highly bound to plasma proteins (99%).
Projected row 76
- Medicine slug
- ambrisentan
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e20ab2fe-bc9f-48a3-b15a-e4bc9532c2ac (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32549c43-f8ff-422c-b42d-ca0877e661cf (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:725d4e73-6c83-477a-adc6-0ae4a133a844 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e418384-cae1-47ae-ac5e-afc845d694f6 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4396bab5-2851-62ef-e063-6294a90af76e (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37af3191-0ed3-4783-8747-065f1462f2d2 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4978a54-1799-43d6-85dd-05fa9de0a5d7 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:291a782a-77e1-8a8e-e1c8-2626f305c2b7 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8080b009-361b-4505-b09a-0d91a0e4a2c0 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fc6032f-94dc-4067-8b24-01990ec99db0 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dcdea4-d3da-4dc1-9193-6ebdb5b4e690 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82e51c75-fb78-4ad3-8bce-5e0581d60014 (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fda3e8b5-267b-4690-85c2-78626986245c (opens source in a new tab)
Ambrisentan label
Version not recorded · Effective date not recorded
Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients.
Projected row 77
- Medicine slug
- amikacin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 8
- Source count
- 7
- Agreement rate
- 0.857143
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20fa61ef-11e2-4d01-82ea-b5412cefaead (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b56f6df-a05d-4520-8bf0-d7cefe20f6ad (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840ba25a-d60c-4f0d-a084-71b0c68237df (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f260ff2a-76a0-4672-9516-91c344b67890 (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7791d3e1-9287-4f75-b4f0-e5d35cacfd6e (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a43188fa-f228-4acd-8a5d-9a3462034f4b (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
5.9 to 19.5 hrs
- Numeric value
- 5.9
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:499ab990-2b21-474f-aaba-d86388965f40 (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
Elimination Following inhalation of ARIKAYCE in MAC patients, the apparent serum half-life of amikacin ranged from approximately 5.9 to 19.5 hrs.
Projected row 78
- Medicine slug
- amikacin
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 8
- Source count
- 7
- Agreement rate
- 0.857143
- Recorded readings
0 to 11%
- Numeric value
- 0
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20fa61ef-11e2-4d01-82ea-b5412cefaead (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b56f6df-a05d-4520-8bf0-d7cefe20f6ad (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840ba25a-d60c-4f0d-a084-71b0c68237df (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f260ff2a-76a0-4672-9516-91c344b67890 (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7791d3e1-9287-4f75-b4f0-e5d35cacfd6e (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a43188fa-f228-4acd-8a5d-9a3462034f4b (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%.
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:499ab990-2b21-474f-aaba-d86388965f40 (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
Distribution The protein binding of amikacin in serum is ≤ 10%.
Projected row 79
- Medicine slug
- amikacin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 8
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
24 liters
- Numeric value
- 24
- Unit
- L
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20fa61ef-11e2-4d01-82ea-b5412cefaead (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b56f6df-a05d-4520-8bf0-d7cefe20f6ad (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:840ba25a-d60c-4f0d-a084-71b0c68237df (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f260ff2a-76a0-4672-9516-91c344b67890 (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7791d3e1-9287-4f75-b4f0-e5d35cacfd6e (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a43188fa-f228-4acd-8a5d-9a3462034f4b (opens source in a new tab)
Amikacin label
Version not recorded · Effective date not recorded
General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight).
Projected row 80
- Medicine slug
- amiloride
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
6 to 9 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b70cf0c-45be-428f-b396-5001ed4e30fc (opens source in a new tab)
Amiloride label
Version not recorded · Effective date not recorded
Peak plasma levels are obtained in 3 to 4 hours and the plasma half-life varies from 6 to 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0cc2d44-436a-47e8-a890-589882fff4c4 (opens source in a new tab)
Amiloride label
Version not recorded · Effective date not recorded
Peak plasma levels are obtained in 3 to 4 hours and the plasma half-life varies from 6 to 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de12b6f3-3791-4d78-90e6-c487cf951738 (opens source in a new tab)
Amiloride label
Version not recorded · Effective date not recorded
Peak plasma levels are obtained in 3 to 4 hours and the plasma half-life varies from 6 to 9 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=70Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.